Postmarketing safety of [ <sup>177</sup> Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system
The findings provide new insights into the adverse events of [<sup>177</sup>Lu]Lu-PSMA-617 and valuable references for clinical applications of radioligand therapy for mCRPC.
Authors
- Xinming Zhao (ORCID: https://orcid.org/0000-0002-7060-2643)
- Na Wang (ORCID: https://orcid.org/0000-0002-7838-170X)
- Zhaoqi Zhang (ORCID: https://orcid.org/0000-0002-7049-6609)
- Yan Zhao (ORCID: https://orcid.org/0000-0002-8408-2458)
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1080/14740338.2025.2466673
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00